Ze‐Rui Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ze‐Rui Sun has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Dong Chang
Yunnan Academy of Scientific & Technical Information Kunming China
1 shared publicationHui‐Zhen Peng
School of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicinal Resource, School of Basic Medicine, Yunnan University of Chinese Medicine Kunming China
1 shared publicationJun Sheng
Key Laboratory of Pu‐erh Tea Science, Ministry of Education College of Science, College of Food Science and Technology, Yunnan Agricultural University Kunming China
1 shared publicationLi‐Juan Zhang
School of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicinal Resource, School of Basic Medicine, Yunnan University of Chinese Medicine Kunming China
1 shared publicationMao‐Si Fan
Key Laboratory of Pu‐erh Tea Science, Ministry of Education College of Science, College of Food Science and Technology, Yunnan Agricultural University Kunming China
1 shared publicationMeng‐Fei An
Key Laboratory of Pu‐erh Tea Science, Ministry of Education College of Science, College of Food Science and Technology, Yunnan Agricultural University Kunming China
1 shared publication
Latest Publications
- 9 April 2025
- Published by Wiley in Journal of the Science of Food and Agriculture
- Vol. 105 (8) , 4178-4190
Dihydromyricetin ameliorates hyperuricemia through inhibiting uric acid reabsorption
BACKGROUND: Hyperuricemia (HUA) is a chronic disease caused by abnormal purine metabolism with high prevalence. Dihydromyricetin (DMY) is a natural flavonoid that is abundant in plants, such as vine tea, grapes and bayberry. DMY has been shown to possess multiple biological properties, but its anti‐HUA effect remains underexplored. In the present study, the regulatory effects of DMY on HUA and its complications and mechanism were investigated.RESULTS: DMY (10 and 20 μmol L−1) treatment significantly reduced xanthine oxidase (XOD) expression and uric acid (UA) synthesis in normal human liver cell strain cells, and intraperitoneal administration of DMY (100 mg kg−1) also significantly reduced serum UA and the expression of hepatic XOD in HUA mice. After DMY treatment for 12 consecutive days, the uricosuric protein, ATP‐binding cassette subfamily G member 2, was upregulated, and reabsorption proteins, including urate transporter 1 and glucose transporter 9, were downregulated, which was consistent with the results of monosodium urate‐induced HUA in human renal tubular epithelial cell line and human colon adenocarcinoma cell line cell models. In addition, DMY significantly ameliorated HUA‐induced renal injury, and foot edema induced by monosodium urate. The nucleotide‐binding oligomerization domain‐like receptor family containing pyrin domain 3 (NLRP3) inflammasome was activated in HUA mice as evidenced by upregulation of NLRP3, caspase‐1, ACS, TNF‐α and IL‐1β in the kidney and foot, which was significantly suppressed by DMY treatment.CONCLUSION: Collectively, these findings suggested that DMY may play important roles in experimental HUA. © 2025 Society of Chemical Industry.
- 9 April 2025
- Published by Wiley in Journal of the Science of Food and Agriculture
- Vol. 105 (8) , 4178-4190
Dihydromyricetin ameliorates hyperuricemia through inhibiting uric acid reabsorption
BACKGROUND: Hyperuricemia (HUA) is a chronic disease caused by abnormal purine metabolism with high prevalence. Dihydromyricetin (DMY) is a natural flavonoid that is abundant in plants, such as vine tea, grapes and bayberry. DMY has been shown to possess multiple biological properties, but its anti‐HUA effect remains underexplored. In the present study, the regulatory effects of DMY on HUA and its complications and mechanism were investigated.RESULTS: DMY (10 and 20 μmol L−1) treatment significantly reduced xanthine oxidase (XOD) expression and uric acid (UA) synthesis in normal human liver cell strain cells, and intraperitoneal administration of DMY (100 mg kg−1) also significantly reduced serum UA and the expression of hepatic XOD in HUA mice. After DMY treatment for 12 consecutive days, the uricosuric protein, ATP‐binding cassette subfamily G member 2, was upregulated, and reabsorption proteins, including urate transporter 1 and glucose transporter 9, were downregulated, which was consistent with the results of monosodium urate‐induced HUA in human renal tubular epithelial cell line and human colon adenocarcinoma cell line cell models. In addition, DMY significantly ameliorated HUA‐induced renal injury, and foot edema induced by monosodium urate. The nucleotide‐binding oligomerization domain‐like receptor family containing pyrin domain 3 (NLRP3) inflammasome was activated in HUA mice as evidenced by upregulation of NLRP3, caspase‐1, ACS, TNF‐α and IL‐1β in the kidney and foot, which was significantly suppressed by DMY treatment.CONCLUSION: Collectively, these findings suggested that DMY may play important roles in experimental HUA. © 2025 Society of Chemical Industry.